Vetoquinol (VETO.PA): analysis and signal as of September 3, 2026
In short
The system delivers a weak signal on Vetoquinol, with a 3/3 vote in neutral layers and a deterministic score that has moved from plus 4,00 to plus 2,50. The main reason lies in a defensive profile contradicted by the decline in reported revenue and by bearish technical momentum.
- Current signal
- weak (vote 3/3)
- Deterministic score
- +2.5 → signal expected by the scale : moderate (September 10, 2026)
- Layers
- fundamentals : neutral, price : –, risks : neutral
Triggered rules
| Rule | Weight |
|---|---|
| favors robust fundamental health (high Piotroski F-Score) | +1.5 |
| favors high gross profitability (gross profit / assets), a robust predictor of returns | +1.0 |
Thesis
Three neutral layers out of three, with a deterministic score that has moved from plus 4,00 to plus 2,50. Animal health provides a defensive profile and a correlation of 0,03 with the market, but reported revenue is declining and veterinary traffic is depressed. Technical momentum remains bearish, with the price trading below its 50-day and 200-day moving averages. The stock retains diversification interest, though the combination of layers does not produce a strong signal.
Bull case
The Essentiels grew by plus 4,1 percent at constant exchange rates in 2025 and account for 66,3 percent of revenue in the first quarter of 2026, a mix shifting toward products at maturity. The company pays a dividend of 0,93 euro, paid for five fiscal years in a row, and has been repurchasing its own shares since July 2026, two tangible supports for the share price. The low volatility exposure is significant, with a Student's t of 2,0, and the diversification contribution is quantified at 17,3 percent less volatility.
Bear case
The price sits below its 50-day moving average by minus 2,5 percent and below its 200-day moving average by minus 8,5 percent, a bearish configuration. The intraday and overnight structure shows that all long term performance comes from the overnight session, with minus 62 percent cumulated during trading hours over two years, the signature of persistent distribution by European institutions in a narrow family float. The macro classification of defensive health conflicts with the 4,3 percent decline in reported revenue in the first quarter of 2026 and with the drop in clinic attendance reported by MSD Santé Animale. A strong euro at 1,159 penalizes the translation of United States sales, the sector being classified as a disadvantaged exporter. The market capitalization recorded at 836,8 million euros suggests that the 0,4 percent TTF does not apply, which contradicts the hypothesis of a threshold above 1 billion euros, possibly outdated. Short positions, fund flows, the median target, analyst recommendations, volumes and the operating margin remain unverified, depriving the price layer of external confirmation.
Scenarios
Bull scenario, probability 25 percent: a move above the moving averages driven by solid half year results and a recovery in the Essentiels. Central scenario, probability 55 percent: share prices confined to a trading range until the results of 10 September 2026, then reassessment according to the guidance. Bear scenario, probability 20 percent: a break of the invalidation threshold on a weekly close.
Risks
The narrow family float exposes the stock to wide moves and sustains persistent distribution by European institutions, visible in the breakdown of performance between the intraday session and overnight. A weekly close below the recent lows would invalidate the thesis. The absence of consensus data, fund flows and consolidated short positions deprives the analysis of external confirmation, and the operating margin, free cash flow and 2025 net debt remain unavailable.
Upcoming catalysts
| Date | Description |
|---|---|
| T3 2026 revenue |
Signal history (last 12 months)
| Date | Signal | New fact |
|---|---|---|
| weak (3/3) | Unchanged. The weak signal is carried over, with no sufficient new element to modify it. The approach of the half year publication of 10 September 2026 is a calendar detail, not a new results data point. Personal analysis, not advice. | |
| weak (single draw, outside the three-draw protocol) | unchanged | |
| weak (single draw, outside the three-draw protocol) | unchanged |
Frequently asked questions
What is the current signal on Vetoquinol?
The system delivers a weak signal, with a vote of three neutral layers out of three and a deterministic score that has moved from plus 4,00 to plus 2,50. Animal health offers a defensive profile and a correlation of 0,03 with the market, but reported revenue is declining and technical momentum remains bearish. No action follows from it automatically.
Why is the defensive health label being called into question?
The macro classification places the sector in defensive health, but reported revenue declines by 4,3 percent in the first quarter of 2026 and attendance at veterinary clinics is depressed, as reported by MSD Santé Animale. A strong euro at 1,159 moreover penalizes the translation of United States sales, the sector being classified as a disadvantaged exporter. The divergence between the defensive label and the actual figures explains the system's caution.
Which elements support the bull thesis?
The Essentiels grew by plus 4,1 percent at constant exchange rates in 2025 and account for 66,3 percent of revenue in the first quarter of 2026. The company has paid a dividend of 0,93 euro for five consecutive fiscal years and has repurchased its own shares since July 2026. The low volatility exposure is significant, with a Student's t of 2,0.
Which data are missing from the analysis?
Short positions and fund flows are not available, the median price target and analyst recommendations were not extracted despite two attempts, and the average daily volume as well as the 52-week extremes remain unverified. The operating margin, free cash flow and 2025 net debt remain absent. The price layer therefore lacks external confirmation.
Which stock market event is coming soon?
Vetoquinol publishes its half year results on 10 September 2026, a date close to the analysis. This event should make it possible to judge the strength of the business and of the guidance, then to reassess the situation. The central scenario, with a probability of 55 percent, expects share prices to remain within their trading range until this publication, before a reassessment according to the guidance given.
Sources
The official filings below are the issuer's own, matched to this stock by its identifier (LEI, CIK or ISIN). The figures quoted above come from an automated arbitration: they have not been re-checked one by one.
- — Rapports financiers et d'audit semestriels/examens réduits / Rapport financier semestriel (AMF · Informations réglementées périodiques)
- — Inside Information / News release on accounts, results (AMF · Informations réglementées continues)
- — Informations privilégiées / Communiqué sur comptes, résultats (AMF · Informations réglementées continues)
- — FORMULAIRE DE DECLARATION D'ACTIONS ET DE DROITS DE VOTE (AMF · Informations réglementées continues)
- — FORMULAIRE DE DECLARATION D'ACTIONS ET DE DROITS (AMF · Informations réglementées continues)
Automated AI analysis: limitations and transparency
- This content is an automated analysis produced using artificial intelligence. Personal analysis for information purposes — no personalised investment advice. MMR content consists of general research. It does not take account of your financial circumstances, objectives or risk tolerance. Data, analyses and results, including those produced using artificial intelligence, may contain errors, be incomplete or become outdated. No return or outcome is guaranteed. All investments carry a risk of partial or total loss of capital. Past performance and simulations do not predict future results. Before making any decision, check information against original sources and, where necessary, consult an authorised professional. You remain responsible for your investment decisions. This notice does not exclude or limit any liability that cannot legally be excluded or limited.
- Tool and analysis: QDNA, Aurélien Ambert.
- Analysis (arbitration) completed on September 3, 2026; this page was completed on September 3, 2026 at 22:59 (UTC).
- Interests: no position in the stock analysed (VETO.PA) is recorded in the data consulted on (UTC). This does not confirm the absence of holdings or other interests. The situation at the analysis publication date has not been reconstructed.
- This declaration covers only recorded positions in this stock; it is not an exhaustive verification of other interests or remuneration.
- Methodology: analysis chain, score formula and scale described on the public methodology page.
- Analysis horizon: 2035.
See also
- Neighbouring stock in the same sector: AbbVie, Inc. (ABBV)
- All analysed stocks
- Public methodology